How to buy Marinus Pharmaceuticals stock (MRNS)

Marinus Pharmaceuticals is a biotechnology business based in the US. Marinus Pharmaceuticals shares (MRNS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.23 – a decrease of 12.48% over the previous week. Marinus Pharmaceuticals employs 165 staff and has a trailing 12-month revenue of around $30.3 million.

Our top picks for where to buy Marinus Pharmaceuticals stock

Buy Marinus Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Marinus Pharmaceuticals stock price (NASDAQ: MRNS)

Use our graph to track the performance of MRNS stocks over time.

Marinus Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$0.23
52-week range	$0.23 - $11.26
50-day moving average more info button	$0.66
200-day moving average more info button	$2.25
Wall St. target price	$1.47
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.47

Is it a good time to buy Marinus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Marinus Pharmaceuticals price performance over time

Historical closes compared with the close of $0.23 from 2024-12-20

1 week (2024-12-16)	-7.15%
1 month (2024-11-22)	-29.23%
3 months (2024-09-23)	-85.89%
6 months (2024-06-21)	-82.71%

1 year (2023-12-22)	-97.80%
2 years (2022-12-23)	-93.43%
3 years (2021-12-23)	12.26
5 years (2019-12-23)	9.32

Marinus Pharmaceuticals financials

Revenue TTM	$30.3 million
Gross profit TTM	$-55,943,000
Return on assets TTM	-57.75%
Return on equity TTM	-2986.55%
Profit margin	0%
Book value	$0.31
Market Capitalization more info button	$13.4 million

TTM: trailing 12 months

Marinus Pharmaceuticals share dividends

We're not expecting Marinus Pharmaceuticals to pay a dividend over the next 12 months.

Have Marinus Pharmaceuticals's shares ever split?

Marinus Pharmaceuticals's shares were split on a 1:4 basis on 22 September 2020 . So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marinus Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Marinus Pharmaceuticals shares which in turn could have impacted Marinus Pharmaceuticals's share price.

Marinus Pharmaceuticals share price volatility

Over the last 12 months, Marinus Pharmaceuticals's shares have ranged in value from as little as $0.2302 up to $11.26. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marinus Pharmaceuticals's is 1.262. This would suggest that Marinus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Marinus Pharmaceuticals overview

Marinus Pharmaceuticals, Inc. , a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Marinus Pharmaceuticals is owned by insiders or institutions?
Currently 10.943% of Marinus Pharmaceuticals shares are held by insiders and 83.037% by institutions. How many people work for Marinus Pharmaceuticals?
Latest data suggests 165 work at Marinus Pharmaceuticals. When does the fiscal year end for Marinus Pharmaceuticals?
Marinus Pharmaceuticals's fiscal year ends in December. Where is Marinus Pharmaceuticals based?
Marinus Pharmaceuticals's address is: 5 Radnor Corporate Center, Radnor, PA, United States, 19087 What is Marinus Pharmaceuticals's ISIN number?
Marinus Pharmaceuticals's international securities identification number is: US56854Q1013 What is Marinus Pharmaceuticals's CUSIP number?
Marinus Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 56854Q101